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rence [4,6–8]. Whether anti-TNF-induced liver damage reﬂects
drug-induced immune-mediated liver injury, or induction of de
novo autoimmune hepatitis remains controversial [9]. Typically,
liver biopsies from these patients exhibit many of the classical
features of AIH, and immunosuppressive therapy is typically
required for resolution of liver inﬂammation [4–8]. However,
the lack of chronicity or disease relapse on withdrawal of immu-
nosuppression favors drug-induced immune-mediated liver
injury.
Although anti-TNF-induced AIH is uncommon, it is being
increasingly described. We report two cases of severe AIH associ-
ated with anti-TNF therapy. In both cases, the patients responded
to withdrawal of anti-TNF therapy and immunosuppressive treat-
ment. Our cases and other reports of anti-TNF-induced AIH, cou-
pled with the recent report by Weiler-Normann et al. [1],
highlight important paradoxical clinical effects of anti-TNF ther-
apy; having the capacity to both ameliorate and induce AIH. A
number of studies have deﬁned both pro-inﬂammatory and
anti-inﬂammatory effects of TNF, mainly through the differential
activation of the two TNF receptors (TNFR1 and TNFR2) expressed
on T cells [10]. Speciﬁcally, TNF can activate effector T cell func-
tion, mainly through TNFR1, which drives inﬂammatory
responses [10,11]. In contrast, TNF stimulation of TNFR2
expressed on regulatory T cells expands the highly suppressive
pool of these cells, which in turn prevents autoimmunity and
attenuates inﬂammation [11]. Therefore, anti-TNF therapy may
either induce or suppress autoimmune inﬂammatory responses
by altering the balance between effector and regulatory T cell
activation [11]. In addition, differential hepatic immune
responses to anti-TNF therapy may also be inﬂuenced by host
genetics and the hepatic microenvironment (e.g., cytokine milieu,
TNFR expression proﬁle, cellular sources of TNF). These potential
explanations for the opposing effects of anti-TNF therapy in
liver autoimmunity should be examined in future studies in this
ﬁeld.
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Open access underReply to: ‘‘Anti-TNF-induced autoimmune hepatitis’’To the Editor:
We would like to thank Dr. Borman [1] and colleagues for their
case presentations illustrating the potentially harmful impact of
anti-TNF-agents on the liver: In this case in their ability to induce
autoimmune hepatitis (AIH). We have previously shown that
inﬂiximab, one of the anti-TNF-drugs, may successfully treat
AIH in selected difﬁcult-to-treat cases [2].
It is well known, that autoimmune features may occur dur-
ing treatment with anti-TNF-agents, especially the emergence
of anti-dsDNA-antibodies has been described in up to 30% of
the patients [3]. Yet, not all patients who develop autoantibod-
ies will also develop clinical symptoms or disease. Further on,
most patients at risk are likely to have a strong genetic back-Journal of Hepatology 20
 CC BY-NC-ND license.ground for the development of autoimmune diseases as anti-
TNF-agents are primarily used to treat autoimmune diseases.
Therefore, it seems necessary to discriminate between de novo
autoimmune diseases in genetically prone patients and paradox-
ical inﬂammation that may also develop as a consequence of
use of these agents. Especially for inﬂiximab, the oldest among
the recombinant antibodies (and unlike etanercept as a soluble
receptor also binding to cell-bound TNF), a wide number of
immunological side effects have been described [4], among oth-
ers psoriasis-like lesions, lupus like syndrome, systemic lupus
erythematodes, (paradoxical) joint inﬂammation, (de-novo)
inﬂammatory bowel disease, uveitis as well as different forms
of vasculitis [5].14 vol. 61 j 169–182
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Also, there are some case reports describing exacerbations of
the underlying treated disease when applying anti-TNF-drugs.
The potential mechanism of how anti-TNF-drugs induce this
paradoxical inﬂammation is unknown and most likely, there
are several phenomena contributing:
(1) There is a high likelihood of genetic predisposition in
patients developing paradoxical inﬂammation or de novo
autoimmune diseases. Unfortunately, the vast majority of
patients with new onset immunological diseases or symp-
toms (e.g., AIH as described by Borman et al. in this issue)
have not been HLA-typed. Most likely, these are individu-
als with a strong genetic predisposition for AIH (namely
e.g., HLA-DRB1⁄0301 or HLA-DRB1⁄0401 positive in the
case of new onset or drug-triggered AIH).
(2) Anti-TNF may block or decrease production of (immuno-
suppressive) glucocorticoids in end-organs and thereby
may contribute to promotion of inﬂammation [6]. In an
experimental setting, lack of TNF may increase the level
of inﬂammation [7].
(3) Anti-TNF-antibodies may bind to cell-bound TNF and
thereby induce apoptosis in these cells [10]. Cell death
may lead to the release of nucleolus-derived antigens
and thereby induce autoantibodies directed against nucle-
osome autoantigens in patients who are genetically
susceptible.
(4) The down-regulation of TNF may lead to an upregulation
of IL-10 which leads to an activation of (autoreactive) B
cells, it may also lead to a general upregulation of a TH2-
immune response.
(5) It has been noted that the presence of anti-cardiolipin anti-
bodies and bacterial infections have been associated in
patients on anti-TNF-drugs. It has been postulated that
unmethylated CpG motifs of bacterial antigens can activate
CD86-expression, which may lead to IL-6-expression in B
cells and synthesis of IFN-gamma, by NKT and TH1 cells.
This may then lead to paradoxical inﬂammation in affected
patients [5].
One main question remains unanswered by this and other
reports on anti-TNF- induced liver injury: Did these patients
really suffer from drug-induced AIH or rather from immune-
mediated drug-induced liver injury (DILI) [8]? The presence of
ﬁbrosis suggests that these patients most likely have predispos-
ing features (and in the report by Borman and colleagues espe-
cially in the latter patient, who had exhibited liver enzyme
elevations even before the initiation of inﬂiximab treatment,
AIH with low activity cannot be ruled out) and therefore, ‘‘true’’
AIH triggered by inﬂiximab remains more likely. The other ques-
tion that is not fully understood is why re-exposure to other anti-
TNF-drugs in most patients did not lead to a relapse of AIH. Is it
because of a different kinetic or route of application of the drug
(adalimumab, certolizumab as well as golimumab are adminis-
tered subcutaneously vs. inﬂiximab, that is infused intrave-
nously) or the different type of antibody (partly or fully
humanized vs. soluble receptor)?
In general, the safety proﬁle of the anti-TNF-drugs is accept-
able and the risk of liver enzyme elevation for patients on TNF-
antagonists is very low [9]. Therefore, anti-TNF-agents remain
safe for the vast majority of patients.Journal of Hepatology 20For the off-label use in autoimmune hepatitis, it seems impor-
tant to select patients eligible for this kind of rescue-treatment
carefully. Patients receiving this rescue-treatment should have
shown failure towards conventional treatment. In addition, dis-
ease activity should be conﬁrmed by elevated transaminases
and the demonstration of inﬂammation on liver biopsy. Finally,
treatment should be monitored closely.
In future, it may be feasible to individualize treatment even to
the point that pre-treatment cytokine levels could be measured
in order to make sure, that the patients identiﬁed for such treat-
ment truly have a predominant TH1-response.
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